title: Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
abstract: To determine the immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in specific populations at risk, we administered vaccine to children with sickle cell anemia (n = 19; mean age, 18.3 months, malignancies (n = 18; mean age, 43.1 months), or a recent history of systemic H. influenzae type b infection (n = 17; mean age, 11.9 months). After one dose of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine the geometric mean titers for polyribosylribitol phosphate antibody were 4.8 micrograms/ml (14/19 greater than 1 microgram/ml), 1.4 micrograms/ml (9/18 greater than 1 microgram/ml), and 5.6 micrograms/ml (15/17 greater than 1 microgram/ml) in these three groups, respectively. Children with sickle cell anemia or a recent history of systemic H. influenzae type b infection had polyribosylribitol phosphate antibody levels comparable to those of normal children of similar age after one or two doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine. We conclude that this vaccine is immunogenic in children with underlying conditions associated with an increased risk of H. influenzae type b infection.
authors.affiliation: Department of Pediatrics, Baylor College of Medicine, Houston, TX.
authors.forename: S L
authors.initials: SL
authors.lastname: Kaplan
authors.forename: T
authors.initials: T
authors.lastname: Duckett
authors.forename: D H
authors.initials: DH
authors.lastname: Mahoney
authors.forename: L L
authors.initials: LL
authors.lastname: Kennedy
authors.forename: C M
authors.initials: CM
authors.lastname: Dukes
authors.forename: D M
authors.initials: DM
authors.lastname: Schaffer
authors.forename: E O
authors.initials: EO
authors.lastname: Mason
mesh_terms: D000755:Anemia, Sickle Cell / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000276:immunology*; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000276:immunology*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D010428:Pentosephosphates / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D010428:Pentosephosphates; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; C003191:polyribose phosphate